|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Goat / IgG|
|Immunogen||Synthetic peptide corresponding to residues CLATEDADSENSSFYYYDYLDEVAFML of human CCRD6.|
|Purification||Antigen affinity chromatography|
|Storage buffer||0.01M potassium phosphate, pH 7.2, with 0.14M NaCl, 1mg/ml BSA|
|Contains||0.1% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1-3 µl for 10^6 cells in 100 µl|
|Immunohistochemistry (Paraffin) (IHC (P))||1:250|
|Western Blot (WB)||1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA1-21614 detects Chemokine Receptor D6 in human samples.
PA1-21614 has been successfully used in ELISA, FACS, immunocytochemistry, immunohistochemistry (paraffin) and Western blot procedures.
The PA1-21614 immunogen is a synthetic peptide corresponding to residues CLATEDADSENSSFYYYDYLDEVAFML of human CCRD6.
Peptide sequence is <50 % identical to other human chemokine receptors in this region.
This gene encodes a beta chemokine receptor similar to G protein-coupled receptors. Chemokines and the receptor-mediated signal transduction are critical for the recruitment of effector immune cells to the inflammation site. This receptor appears to bind the majority of beta-chemokine family members; however, its specific function remains unkown.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Host genotype and tumor phenotype of chemokine decoy receptors integrally affect breast cancer relapse.
PA1-21614 was used in immunohistochemistry - paraffin section to determine chemokine decoy receptor expression in breast cancer samples
|Yu KD,Wang X,Yang C,Zeng XH,Shao ZM||Oncotarget (6:26519)||2015|
Absence of multiple atypical chemokine binders (ACBs) and the presence of VEGF and MMP-9 predict axillary lymph node metastasis in early breast carcinomas.
PA1-21614 was used in immunohistochemistry to examine the prognostic value of multiple atypical chemokine binders, VEGF and MMP-9
|Zeng XH,Ou ZL,Yu KD,Feng LY,Yin WJ,Li J,Shen ZZ,Shao ZM||Medical oncology (Northwood, London, England) (31:null)||2014|
Coexpression of atypical chemokine binders (ACBs) in breast cancer predicts better outcomes.
PA1-21614 was used in immunohistochemistry to investigate the expression profile of atypical chemokine binder D6, DARC, D6 in breast cancer
|Zeng XH,Ou ZL,Yu KD,Feng LY,Yin WJ,Li J,Shen ZZ,Shao ZM||Breast cancer research and treatment (125:715)||2011|
Chemokine decoy receptor d6 plays a negative role in human breast cancer.
PA1-21614 was used in immunohistochemistry to study how the growth and metastasis of human breast cancer is influenced by D6
|Wu FY,Ou ZL,Feng LY,Luo JM,Wang LP,Shen ZZ,Shao ZM||Molecular cancer research : MCR (6:1276)||2008|